Delhi High Court Upholds BMS’ Patent for Cancer Drug Dasatinib

Monday, July 6, 2015

Source: The Economic Times

The Delhi High Court has upheld the patent of US-based Bristol Myers Squibs (BMS) for Dasatinib, dashing the hopes of a local company to sell a generic version of the cancer drug and providing some relief to multinational drugmakers who are up in arms against India's patent laws.


View All News »